| Stephani Simon Luecker, DO | |
|
1145 W Redondo Beach Blvd, Gardena, CA 90247-3528 | |
| (310) 538-6629 | |
| Not Available |
| Full Name | Stephani Simon Luecker |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 17 Years |
| Location | 1145 W Redondo Beach Blvd, Gardena, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659494557 | NPI | - | NPPES |
| 20A11735 | Other | CA | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 20A11735 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stat Med Pc A California Medical Professional Corporation | 1850528530 | 14 |
News Archive
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
BLOCKING a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research presented at the National Cancer Research Institute Cancer Conference in Liverpool.
Harris Health System is the only healthcare system in the nation awarded a $150,000 grant to help the U.S. Department of Health and Human Services (HHS) develop and improve ways to share cybersecurity threat information and protect the critical cyber infrastructure of the nation's public and private healthcare sector.
In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.
› Verified 1 days ago
| Entity Name | Vallejo Emergency Physicians Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083916373 PECOS PAC ID: 2961683693 Enrollment ID: O20110228000897 |
News Archive
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
BLOCKING a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research presented at the National Cancer Research Institute Cancer Conference in Liverpool.
Harris Health System is the only healthcare system in the nation awarded a $150,000 grant to help the U.S. Department of Health and Human Services (HHS) develop and improve ways to share cybersecurity threat information and protect the critical cyber infrastructure of the nation's public and private healthcare sector.
In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.
› Verified 1 days ago
| Entity Name | Redondo Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376834937 PECOS PAC ID: 9032388269 Enrollment ID: O20110804000471 |
News Archive
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
BLOCKING a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research presented at the National Cancer Research Institute Cancer Conference in Liverpool.
Harris Health System is the only healthcare system in the nation awarded a $150,000 grant to help the U.S. Department of Health and Human Services (HHS) develop and improve ways to share cybersecurity threat information and protect the critical cyber infrastructure of the nation's public and private healthcare sector.
In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.
› Verified 1 days ago
| Entity Name | Stat Med Pc A California Medical Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891132106 PECOS PAC ID: 1850528530 Enrollment ID: O20140204000122 |
News Archive
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
BLOCKING a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research presented at the National Cancer Research Institute Cancer Conference in Liverpool.
Harris Health System is the only healthcare system in the nation awarded a $150,000 grant to help the U.S. Department of Health and Human Services (HHS) develop and improve ways to share cybersecurity threat information and protect the critical cyber infrastructure of the nation's public and private healthcare sector.
In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephani Simon Luecker, DO Po Box 660446, Arcadia, CA 91066-0446 Ph: (626) 447-0296 | Stephani Simon Luecker, DO 1145 W Redondo Beach Blvd, Gardena, CA 90247-3528 Ph: (310) 538-6629 |
News Archive
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
BLOCKING a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research presented at the National Cancer Research Institute Cancer Conference in Liverpool.
Harris Health System is the only healthcare system in the nation awarded a $150,000 grant to help the U.S. Department of Health and Human Services (HHS) develop and improve ways to share cybersecurity threat information and protect the critical cyber infrastructure of the nation's public and private healthcare sector.
In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.
› Verified 1 days ago
Dr. Taylor Walsh, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1145 W Redondo Beach Blvd, Gardena, CA 90247 Phone: 310-532-4200 | |
Dr. Patrick L. Ignacio, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1149 W 190th St, Gardena, CA 90248 Phone: 310-324-5777 Fax: 310-324-6245 | |
Chioma Pamela Onodugo, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1225 W 190th St Ste 280, Gardena, CA 90248 Phone: 310-515-8113 Fax: 310-538-2102 | |
Hang T Tran, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1145 W Redondo Beach Blvd, Gardena, CA 90247 Phone: 310-538-6629 | |
Keivan Edalat, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1145 West Redondo Beach Blvd, Gardena, CA 90247 Phone: 310-538-6629 | |
Ivy Chang, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1145 W Redondo Beach Blvd, Gardena, CA 90247 Phone: 310-538-6629 |